Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Biotechnology

Healthcare
$92.49 +3.81%

+$3.89 today

Market cap
$6.04B
Beta
0.51
P/E (TTM)
-7.8
EPS (TTM)
-$13.57
52W Low $47.89High $114.99

Volume 0.50M

Average 0.95M

MIRM Sales of Investments

Cash received from selling or redeeming investments.

Mirum Pharmaceuticals, Inc.NASDAQ: MIRM

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments growth accelerates

Q2 FY2026 sales of investments of $59.74M rose 138.3% year over year, ahead of the +101.2% change in trailing-twelve-month sales of investments. Sequentially, it rose 76.3% from the prior quarter. Over 3 fiscal years it compounded at -19.0% a year.

Context

  • Sales of investments amounted to 14.3% of revenue in FY2025, up 8.4 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +138.3% holds above the trailing-twelve-month pace of +101.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$59.74M+76.3% QoQ
Last fiscal yearDec 2025
$74.43M+274.1% YoY
LTMJun 2026
$125.56M+101.2% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+138.3%——
1 year+274.1%——
3-year CAGR-19.0%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
74.43M USD
Year-over-year change
+274.1%
4-year CAGR
-17.1%

Sales of Investments vs competitors

How MIRM compares with its peers on the latest reported figures

  • MIRM's LTM Jun 2026 sales of investments of $125.56M is the 7th largest of the 8 companies compared; the peer median is $287.42M.
  • Its year-over-year change of +101.2% is the highest of 7, against a peer median of +5.4%.
  • Sales of investments amounts to 20.3% of revenue for MIRM, versus a peer median of 82.5%.
MIRM Competitors Peer median
Sales of Investments for MIRM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$1.06B -2.4%+45.9%82.5%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$1.04B +40.3%-3.4%1567.4%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$395.01M -5.6%-6.6%59.0%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$287.42M +13.1%+4.8%415.3%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$246.48M -16.8%-5.4%37.9%
ALTAltimmune, Inc.LTM Mar 2026$154.57M +38.8%—429355.6%
MIRMMirum Pharmaceuticals, Inc.LTM Jun 2026$125.56M +101.2%-19.0%20.3%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding MIRM) $287.42M+5.4%-3.4%82.5%

Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.99M)(135.67M)(163.42M)(87.94M)(23.36M)
Depreciation & Amortization975K3.24M10.83M23.63M24.24M
Deferred Income Tax595K(6.58M)000
Stock-Based Compensation23.09M27.01M35.02M48.44M71.42M
Change in Working Capital16.98M(21.05M)(22.64M)22.59M(19.72M)
Accounts Receivables0(20.73M)(43.97M)(11.43M)(48.06M)
Inventory(495K)(3.45M)(4.39M)(3.17M)(8.45M)
Accounts Payables22.66M7.64M30.78M40.31M50.1M
Other Working Capital(5.18M)(4.51M)(5.05M)(3.13M)(13.32M)
Other Non-Cash Items(90.41M)12.91M69.26M3.6M3.24M
Operating Cash Flow(132.76M)(120.14M)(70.94M)10.33M55.83M
Capital Expenditures(19.02M)(278K)(20.11M)(993K)(954K)
Acquisitions (Net)(19M)(7.98M)(212.76M)00
Purchases of Investments(198.03M)(132.32M)(27.33M)(89.03M)(97.43M)
Sales of Investments157.6M140.3M153M19.89M74.43M
Other Investing Activities127M7.98M(20M)(20M)0
Investing Cash Flow48.55M7.7M(107.2M)(90.13M)(23.95M)
Debt Repayment00305.3M00
Common Stock Issued6.91M107.37M216.68M17.7M40.14M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities66.55M1.72M(185.39M)00
Financing Cash Flow73.47M109.09M336.6M17.7M40.14M
Effect of Forex Changes(1K)12K(133K)(1.3M)3.22M
Net Change in Cash(10.75M)(3.34M)158.32M(63.4M)75.24M
Free Cash Flow(151.78M)(120.41M)(91.05M)9.33M54.87M

Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Intrinsic Alpha fair value

Locked

Current Price

$92.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.